- Home
- ANIP vs CSAN Comparison
ANIP vs CSAN Comparison
Compare ANIP & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIP
- CSAN
- Stock Information
- Founded
- ANIP 2001
- CSAN 1936
- Country
- ANIP United States
- CSAN Brazil
- Employees
- ANIP N/A
- CSAN N/A
- Industry
- ANIP Biotechnology: Pharmaceutical Preparations
- CSAN Retail-Auto Dealers and Gas Stations
- Sector
- ANIP Health Care
- CSAN Consumer Discretionary
- Exchange
- ANIP Nasdaq
- CSAN Nasdaq
- Market Cap
- ANIP 2.0B
- CSAN 2.0B
- IPO Year
- ANIP N/A
- CSAN N/A
- Fundamental
- Price
- ANIP $98.30
- CSAN $5.48
- Analyst Decision
- ANIP Strong Buy
- CSAN Buy
- Analyst Count
- ANIP 9
- CSAN 2
- Target Price
- ANIP $86.00
- CSAN $12.00
- AVG Volume (30 Days)
- ANIP 488.4K
- CSAN 1.8M
- Earning Date
- ANIP 11-07-2025
- CSAN 08-14-2025
- Dividend Yield
- ANIP N/A
- CSAN N/A
- EPS Growth
- ANIP N/A
- CSAN N/A
- EPS
- ANIP N/A
- CSAN N/A
- Revenue
- ANIP $747,399,000.00
- CSAN $7,993,490,490.00
- Revenue This Year
- ANIP $39.32
- CSAN $271.59
- Revenue Next Year
- ANIP $9.62
- CSAN $1.72
- P/E Ratio
- ANIP N/A
- CSAN N/A
- Revenue Growth
- ANIP 38.68
- CSAN 7.98
- 52 Week Low
- ANIP $52.50
- CSAN $3.80
- 52 Week High
- ANIP $99.50
- CSAN $10.12
- Technical
- Relative Strength Index (RSI)
- ANIP 77.93
- CSAN 72.38
- Support Level
- ANIP $96.50
- CSAN $5.20
- Resistance Level
- ANIP $99.50
- CSAN $5.53
- Average True Range (ATR)
- ANIP 2.17
- CSAN 0.19
- MACD
- ANIP -0.33
- CSAN 0.14
- Stochastic Oscillator
- ANIP 87.17
- CSAN 96.64
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.